Venezuela Medical Device Regulation: Authorized Representative Selection and Liability

1. Key takeaways

A foreign medical device manufacturer that registers a product in Venezuela must appoint a locally established Venezuelan entity as its authorized representative (Representante Autorizado). The appointment is not a contact window and not a marketing agent. The representative is the party that carries legal responsibility for the product before it is placed on the market, and it remains the party of record for as long as the registration stays alive.

The conclusion is that choosing an authorized representative is a one-off, expensive and barely reversible decision. If the choice turns out badly, whether because the entity lacks the qualifications, because it does not cooperate, or because it ceases to trade, replacing it requires the outgoing representative to cooperate, and the outgoing representative has no legal duty to do so. That asymmetry, not the fee level, is the hardest risk to remedy in a Venezuelan project.

Three consequences follow directly. First, the registration certificate is tied to the entity, not to the product, so the manufacturer’s market access survives only as long as the entity does. Second, platform access is account-based, which means the manufacturer cannot file, correct or pay anything without the representative holding the credentials. Third, the sanitary conformity duties at import land on the same entity, so a representative that is weak at inspection is a representative that is weak at clearance. All three point to the same discipline: treat selection as a diligence exercise with written criteria, not as a purchasing decision made on price and speed.

2. Legal basis

The instruments below define the registration duty and the procedural role of the representative. Citations are reproduced exactly as they appear in the Venezuelan sources.

Basis note: the rule that a foreign manufacturer must appoint a local authorized representative comes from industry sources and is marked as a practical estimate rather than a verbatim statutory quotation.

3. Expert insights

Insight 1: the role was materially strengthened by the 2025 platform migration. Under paper filing, the representative was mainly a courier of documents: it assembled the dossier, delivered it to a counter and collected the response. Under the COMEX platform the same entity is simultaneously the account holder, the applicant, the payer and the responsible party. Consolidating those four functions into one entity raises its irreplaceability. A manufacturer cannot bypass its representative and operate the platform directly, which means the commercial relationship with that entity is now a structural dependency rather than an administrative convenience.

Insight 2: the liability the representative carries often exceeds its commercial substance, and that mismatch is the structural source of risk. The representative answers legally for the product’s compliance in the Venezuelan market, yet many local agencies are small operations with limited capital, few staff and a narrow client base. If such an entity stops trading while a certificate is still valid, the manufacturer is left with a certificate anchored to a legal person that no longer exists. Restoring a clean status then means either reviving the entity or rebuilding the registration from the beginning, and neither route is quick or cheap.

Insight 3: SACS may inspect importers without prior notice. This inspection power (discussed in detail in article 44) falls on the representative and the importer, which means the representative must maintain a standing state of compliance readiness: traceable records, correct storage, current authorizations and staff who know what to produce when an inspector arrives. That is a specific item to test during selection, not a general impression of being experienced. A representative that has never been inspected is not evidence of a clean record; it may simply mean the entity has never carried enough volume to attract attention.

Insight 4: selection criteria should be quantified. The dimensions worth scoring are: legal establishment and current good standing, RIF registration status, the local sanitary licence, hands-on experience with the specific directorate that will handle the file, financial and operational stability, staffing depth, the existing client and product portfolio (looking specifically for competing products), and the documented record of responsiveness on past files. Each dimension should be scored against evidence the candidate supplies, and the score should be recorded, because a decision of this weight will be revisited by auditors, by headquarters and by any successor manager who inherits the file.

4. Practical recommendations

1. Complete due diligence before appointment, covering at minimum the five core dimensions: legal standing, RIF and sanitary licence, directorate-level experience, operational stability, and competing-product conflicts.
2. In the representation agreement, set out notification duties and deadlines (regulatory circulars, deficiency requests, changes in certificate status) together with liquidated damages for breach.
3. Build exit and handover clauses into the power of attorney (article 23), specifying termination triggers and the obligation to hand over documents and platform data.
4. Establish an annual review mechanism that re-tests the representative’s standing and compliance capability every year, instead of treating the appointment as finished once signed.
5. Keep a duplicate copy of every filing, receipt and platform acknowledgement in the manufacturer’s own archive, so that the file can be reconstructed if the relationship ends abruptly.

5. Verification checklist

• □ Due diligence on the representative completed, covering the five core dimensions
• □ Representation agreement sets notification duties, deadlines and liability for breach
• □ Power of attorney includes exit and document handover clauses
• □ Annual review mechanism for the representative established
• □ Representative confirmed to have hands-on COMEX platform experience with the relevant directorate

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers, importers and authorized representatives with registration work in Venezuela, from representative selection and due diligence through dossier preparation, COMEX platform filing and post-approval maintenance. Whether you need a candidate assessment, a representation agreement review, or hands-on filing support, our regulatory team can help. Contact us at info@grzanglobal.com.